Pegylated liposomal doxorubicin is an important antineoplastic agent with activity in a variety of solid tumors. It has a totally different profile of pharmacokinetics and toxicity compared with doxorubicin. It rarely causes side-effects like cardiotoxicity or hair loss, but frequently results in many kinds of mucocutaneous reactions, including palmar-plantar erythrodysesthesia, diffuse follicular rash, intertrigo-like eruption, new formation of melanotic macules, stomatitis and radiation recall dermatitis. We present a rare case of multiple myeloma who immediately developed serious stomatitis and esophatitis associated with minor palmar-plantar erythrodysesthesia after a single course of pegylated liposomal doxorubicin.
CITATION STYLE
Ma, H., Chen, M., Liu, J., Li, Y., & Li, J. (2015). Serious stomatitis and esophagitis: A peculiar mucous reaction induced by pegylated liposomal doxorubicin. Anais Brasileiros de Dermatologia, 90(3), S209–S211. https://doi.org/10.1590/abd1806-4841.20153708
Mendeley helps you to discover research relevant for your work.